A comparative study of 24-hour and 6-hour Infusion of Nafamostat Mesilate for Prevention of Post-ERCP Pancreatitis: a Prospective Randomized Comparison Trial
Latest Information Update: 09 May 2018
At a glance
- Drugs Nafamostat (Primary)
- Indications Pancreatitis
- Focus Therapeutic Use
- 07 Sep 2016 New trial record